Xencor, Inc.

Xencor is a clinical-stage biopharmaceutical company that discovers and develops engineered antibody therapeutics for patients with cancer and autoimmune diseases with unmet medical needs. Its XmAb protein-engineering platforms modify antibody Fc domains to improve biological function or create new therapeutic mechanisms, enabling purpose-built drug candidates. The company advances a broad portfolio through clinical development and also partners with biopharmaceutical companies to license technology and develop antibody and cytokine medicines.